SS-31: The Peptide That Targets the Mitochondrial Inner Membrane
SS-31 (D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH₂), also known by its clinical development name Elamipretide (formerly Bendavia and MTP-131), is a synthetic tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Developed by Hazel Szeto and Peter Bhatt at Weill Cornell Medical College, SS-31 was designed as part of the Szeto-Schiller (SS) peptide series that exploits the mitochondrial membrane potential to achieve 1,000-5,000 fold accumulation in mitochondria (Szeto, 2006).
SS-31's unique mechanism — direct binding to cardiolipin, a phospholipid exclusive to the inner mitochondrial membrane — has made it a breakthrough tool in mitochondrial medicine research.
Molecular Profile
- Sequence: D-Arg-Dmt-Lys-Phe-NH₂ (Dmt = 2',6'-dimethyltyrosine)
- Amino acids: 4 (tetrapeptide with non-natural amino acid)
- Molecular weight: ~640.8 Da
- CAS number: 736992-21-5
- Classification: Mitochondria-targeted antioxidant peptide
- Mitochondrial accumulation: 1,000-5,000x concentration relative to cytosol
- Key target: Cardiolipin in the inner mitochondrial membrane
Mechanism of Action
SS-31's mechanism is centered on its interaction with cardiolipin, a bis-phosphatidylglycerol lipid found exclusively in the inner mitochondrial membrane. Cardiolipin plays essential structural and functional roles in the electron transport chain (ETC) (Birk et al., 2013):
- Cardiolipin binding: SS-31 binds to cardiolipin with high affinity, stabilizing its interaction with cytochrome c and preventing cytochrome c from converting into a peroxidase that damages the membrane
- Electron transport chain optimization: By stabilizing cardiolipin-protein interactions, SS-31 improves electron flow through complexes I, III, and IV, increasing ATP production efficiency
- ROS reduction: Improved electron transport reduces electron leak and superoxide generation at complexes I and III — the primary mitochondrial ROS sources
- Cristae structure preservation: SS-31 helps maintain the folded cristae architecture of the inner membrane, which is critical for oxidative phosphorylation efficiency
Research Area 1: Cardiac Ischemia-Reperfusion Injury
Szeto (2008) demonstrated that SS-31 significantly reduced infarct size in a mouse model of cardiac ischemia-reperfusion injury when administered prior to reperfusion. The protection was attributed to preservation of mitochondrial function during the ischemic period and reduction of ROS burst upon reperfusion.
Kloner et al. (2012) extended these findings to a large animal (sheep) model of acute myocardial infarction, reporting that SS-31 (as Bendavia) reduced infarct size by approximately 20% when administered at the time of coronary reperfusion. This study was pivotal in advancing SS-31 toward clinical trials in acute coronary syndromes.
Research Area 2: Barth Syndrome and Cardiolipin Disorders
Barth syndrome is a rare X-linked genetic disorder caused by mutations in the tafazzin gene, which leads to abnormal cardiolipin remodeling. Patients present with cardiomyopathy, skeletal myopathy, and exercise intolerance. Birk et al. (2013) demonstrated that SS-31 improved mitochondrial function in Barth syndrome patient-derived lymphoblasts, restoring cardiolipin organization and improving cristae structure.
This research led to clinical trials of Elamipretide in Barth syndrome patients, representing one of the most advanced clinical applications of mitochondria-targeted peptide therapy. The TAZPOWER trial investigated Elamipretide's effects on exercise capacity and cardiac function in Barth syndrome patients (Thompson et al., 2021).
Research Area 3: Age-Related Mitochondrial Dysfunction
Siegel et al. (2013) investigated SS-31 in aged mice and demonstrated improvements in mitochondrial function, reduced ROS production, and improved cardiac diastolic function. The aging heart showed restored mitochondrial membrane potential and improved ATP production following SS-31 treatment.
Campbell et al. (2019) showed that short-term SS-31 treatment in aged mice partially reversed age-related decline in skeletal muscle mitochondrial function, improving exercise tolerance and reducing markers of oxidative stress. These findings suggest that age-related mitochondrial dysfunction may be partially reversible through cardiolipin-targeted intervention.
Research Area 4: Kidney Disease
Szeto et al. (2011) demonstrated that SS-31 reduced kidney injury in models of acute kidney injury (AKI) and chronic kidney disease (CKD). Mitochondrial dysfunction plays a central role in renal tubular injury, and SS-31's ability to preserve mitochondrial function in kidney tubular cells was associated with reduced fibrosis and preserved renal function.
This renal research has progressed into clinical trials, with Elamipretide investigated for renal ischemia-reperfusion injury in the context of percutaneous renal angioplasty.
Research Area 5: Neurodegenerative Disease Models
Yang et al. (2009) showed that SS-31 reduced oxidative damage and improved neuronal survival in cell culture models of Alzheimer's disease exposed to amyloid-beta peptide. The mitochondrial protection prevented the cascade of events linking mitochondrial dysfunction to neurodegeneration.
Calkins et al. (2011) demonstrated that SS-31 improved mitochondrial function and reduced oxidative damage in neurons from a transgenic Alzheimer's mouse model, suggesting that early mitochondrial protection may modify disease progression.
Current Research Status
Elamipretide has progressed through multiple clinical trials under Stealth BioTherapeutics, including Phase 2 and Phase 3 studies for Barth syndrome, primary mitochondrial myopathy, and heart failure. While not all trials have met primary endpoints, the compound remains an active area of clinical investigation and has provided substantial evidence for the therapeutic potential of mitochondria-targeted peptide therapy.
Research Disclaimer
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.